Brain efflux index to investigate the influence of active efflux on brain distribution of pemetrexed and methotrexate

Drug Metabolism and Disposition

Volumn 41, Issue 3, 2013, Pages 659-667

  Li, Li ^a   Agarwal, Sagar ^a   Elmquist, William F ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN 2; ORGANIC ANION TRANSPORTER; PEMETREXED; PENICILLIN G; PROBENECID;

ACTIVE TRANSPORT; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG BRAIN LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG TRANSPORT; MALE; MICROINJECTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; CAPILLARY PERMEABILITY; FOLIC ACID ANTAGONISTS; GLUTAMATES; GUANINE; HALF-LIFE; MALE; METHOTREXATE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICROINJECTIONS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; ORGANIC ANION TRANSPORTERS, SODIUM-INDEPENDENT; PENICILLIN G; PROBENECID;

EID: 84874081365     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.112.049254     Document Type: Article

References (42)

1. Allen DD and Smith QR (2001) Characterization of the blood-brain barrier choline transporter using the in situ rat brain perfusion technique. J Neurochem 76:1032-1041.
2. Bakos E, Evers R, Sinkó E, Váradi A, Borst P, and Sarkadi B (2000) Interactions of the human multidrug resistance proteins MRP1 and MRP2 with organic anions. Mol Pharmacol 57: 760-768.
3. Belinsky MG, Guo P, Lee K, Zhou F, Kotova E, Grinberg A, Westphal H, Shchaveleva I, Klein-Szanto A, and Gallo JM, et al. (2007) Multidrug resistance protein 4 protects bone marrow, thymus, spleen, and intestine from nucleotide analogue-induced damage. Cancer Res 67: 262-268.
4. Blakeley JO, Olson J, Grossman SA, He X, Weingart J, and Supko JG; New Approaches to Brain Tumor Therapy (NABTT) Consortium (2009) Effect of blood brain barrier permeability in recurrent high grade gliomas on the intratumoral pharmacokinetics of methotrexate: a microdialysis study. J Neurooncol 91:51-58.
5. Chen ZS, Lee K, Walther S, Raftogianis RB, Kuwano M, Zeng H, and Kruh GD (2002) Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. Cancer Res 62:3144-3150.
6. Dai H, Chen Y, and Elmquist WF (2005) Distribution of the novel antifolate pemetrexed to the brain. J Pharmacol Exp Ther 315:222-229.
7. Devineni D, Klein-Szanto A, and Gallo JM (1996) In vivo microdialysis to characterize drug transport in brain tumors: analysis of methotrexate uptake in rat glioma-2 (RG-2)-bearing rats. Cancer Chemother Pharmacol 38:499-507.
8. El-Sheikh AA, van den Heuvel JJ, Koenderink JB, and Russel FG (2007) Interaction of nonsteroidal anti-inflammatory drugs with multidrug resistance protein (MRP) 2/ABCC2-and MRP4/ABCC4-mediated methotrexate transport. J Pharmacol Exp Ther 320:229-235.
9. Gerstner ER, Carson KA, Grossman SA, and Batchelor TT (2008) Long-term outcome in PCNSL patients treated with high-dose methotrexate and deferred radiation. Neurology 70:401-402.
10. Golden PL and Pollack GM (2003) Blood-brain barrier efflux transport. J Pharm Sci 92: 1739-1753.
11. Haimeur A, Conseil G, Deeley RG, and Cole SP (2004) The MRP-related and BCRP/ABCG2 multidrug resistance proteins: biology, substrate specificity and regulation. Curr Drug Metab 5: 21-53.
12. Hanauske AR, Eismann U, Oberschmidt O, Pospisil H, Hoffmann S, Hanauske-Abel H, Ma D, Chen V, Paoletti P, and Niyikiza C (2007) In vitro chemosensitivity of freshly explanted tumor cells to pemetrexed is correlated with target gene expression. Invest New Drugs 25:417-423.
13. Ieiri I, Higuchi S, and Sugiyama Y (2009) Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs. Expert Opin Drug Metab Toxicol 5:703-729.
14. Ito S, Ohtsuki S, and Terasaki T (2006) Functional characterization of the brain-to-blood efflux clearance of human amyloid-beta peptide (1-40) across the rat blood-brain barrier. Neurosci Res 56:246-252.
15. Kakee A, Takanaga H, Hosoya K, Sugiyama Y, and Terasaki T (2002) In vivo evidence for brainto-blood efflux transport of valproic acid across the blood-brain barrier. Microvasc Res 63: 233-238.
16. Kakee A, Terasaki T, and Sugiyama Y (1996) Brain efflux index as a novel method of analyzing efflux transport at the blood-brain barrier. J Pharmacol Exp Ther 277:1550-1559.
17. Kikuchi R, Kusuhara H, Sugiyama D, and Sugiyama Y (2003) Contribution of organic anion transporter 3 (Slc22a8) to the elimination of p-aminohippuric acid and benzylpenicillin across the blood-brain barrier. J Pharmacol Exp Ther 306:51-58.
18. Kuo T and Recht L (2006) Optimizing therapy for patients with brain metastases. Semin Oncol 33:299-306.
19. Kusuhara H, Sekine T, Utsunomiya-Tate N, Tsuda M, Kojima R, Cha SH, Sugiyama Y, Kanai Y, and Endou H (1999) Molecular cloning and characterization of a new multispecific organic anion transporter from rat brain. J Biol Chem 274:13675-13680.
20. Kusuhara H and Sugiyama Y (2005) Active efflux across the blood-brain barrier: role of the solute carrier family. NeuroRx 2:73-85.
21. Kusuhara H, Suzuki H, Terasaki T, Kakee A, Lemaire M, and Sugiyama Y (1997) P-Glycoprotein mediates the efflux of quinidine across the blood-brain barrier. J Pharmacol Exp Ther 283: 574-580.
22. Kusuhara H, Terasaki T, and Sugiyama Y (2003) Brain efflux index method. Characterization of efflux transport across the blood-brain barrier. Methods Mol Med 89:219-231.
23. Leggas M, Adachi M, Scheffer GL, Sun D, Wielinga P, Du G, Mercer KE, Zhuang Y, Panetta JC, and Johnston B, et al. (2004) Mrp4 confers resistance to topotecan and protects the brain from chemotherapy. Mol Cell Biol 24:7612-7621.
24. Li L, Sham YY, Bikadi Z, and Elmquist WF (2011) pH-Dependent transport of pemetrexed by breast cancer resistance protein. Drug Metab Dispos 39:1478-1485.
25. Miller DS, Nobmann SN, Gutmann H, Toeroek M, Drewe J, and Fricker G (2000) Xenobiotic transport across isolated brain microvessels studied by confocal microscopy. Mol Pharmacol 58:1357-1367.
26. Mori S, Ohtsuki S, Takanaga H, Kikkawa T, Kang YS, and Terasaki T (2004) Organic anion transporter 3 is involved in the brain-to-blood efflux transport of thiopurine nucleobase analogs. J Neurochem 90:931-941.
27. Mori S, Takanaga H, Ohtsuki S, Deguchi T, Kang YS, Hosoya K, and Terasaki T (2003) Rat organic anion transporter 3 (rOAT3) is responsible for brain-to-blood efflux of homovanillic acid at the abluminal membrane of brain capillary endothelial cells. J Cereb Blood Flow Metab 23:432-440.
28. Motl S, Zhuang Y, Waters CM, and Stewart CF (2006) Pharmacokinetic considerations in the treatment of CNS tumours. Clin Pharmacokinet 45:871-903.
29. Norden AD, Drappatz J, Wen PY, and Claus EB (2011) Survival among patients with primary central nervous system lymphoma, 1973-2004. J Neurooncol 101:487-493.
30. Ohtsuki S, Asaba H, Takanaga H, Deguchi T, Hosoya K, Otagiri M, and Terasaki T (2002) Role of blood-brain barrier organic anion transporter 3 (OAT3) in the efflux of indoxyl sulfate, a uremic toxin: its involvement in neurotransmitter metabolite clearance from the brain. J Neurochem 83:57-66.
31. Pardridge WM (1999) Blood-brain barrier biology and methodology. J Neurovirol 5:556-569.
32. Pardridge WM (2001) Crossing the blood-brain barrier: are we getting it right? Drug Discov Today 6:1-2.
33. Pratt SE, Emerick RM, Horwitz L, Gallery M, Lesoon A, Jink S, Chen VJ, and Dantzig AH (2002) Multidrug resistance proteins (MRP) 2 and 5 transport and confer resistance to Alimta. Proc Am Assoc Cancer Res 43: 782.
34. Reinoso RF, Telfer BA, and Rowland M (1997) Tissue water content in rats measured by desiccation. J Pharmacol Toxicol Methods 38:87-92.
35. Sugiyama D, Kusuhara H, Shitara Y, Abe T, Meier PJ, Sekine T, Endou H, Suzuki H, and Sugiyama Y (2001) Characterization of the efflux transport of 17b-estradiol-D-17b-glucuronide from the brain across the blood-brain barrier. J Pharmacol Exp Ther 298:316-322.
36. Suzuki T, Zaima C, Moriki Y, Fukami T, and Tomono K (2007) P-glycoprotein mediates brainto-blood efflux transport of buprenorphine across the blood-brain barrier. J Drug Target 15: 67-74.
37. Takasawa K, Terasaki T, Suzuki H, and Sugiyama Y (1997) In vivo evidence for carrier-mediated efflux transport of 39-azido-39-deoxythymidine and 29,39-dideoxyinosine across the bloodbrain barrier via a probenecid-sensitive transport system. J Pharmacol Exp Ther 281:369-375.
38. Tian X, Li J, Zamek-Gliszczynski MJ, Bridges AS, Zhang P, Patel NJ, Raub TJ, Pollack GM, and Brouwer KL (2007) Roles of P-glycoprotein, Bcrp, and Mrp2 in biliary excretion of spiramycin in mice. Antimicrob Agents Chemother 51:3230-3234.
39. Urquhart BL and Kim RB (2009) Blood-brain barrier transporters and response to CNS-active drugs. Eur J Clin Pharmacol 65:1063-1070.
40. Vlaming ML, Mohrmann K, Wagenaar E, de Waart DR, Elferink RP, Lagas JS, van Tellingen O, Vainchtein LD, Rosing H, and Beijnen JH, et al. (2006) Carcinogen and anticancer drug transport by Mrp2 in vivo: studies using Mrp2 (Abcc2) knockout mice. J Pharmacol Exp Ther 318:319-327.
41. Vlaming ML, Pala Z, van Esch A, Wagenaar E, de Waart DR, van de Wetering K, van der Kruijssen CM, Oude Elferink RP, van Tellingen O, and Schinkel AH (2009) Functionally overlapping roles of Abcg2 (Bcrp1) and Abcc2 (Mrp2) in the elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate in vivo. Clin Cancer Res 15:3084-3093.
42. Volk EL and Schneider E (2003) Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res 63:5538-5543.